Tenax Therapeutics shareholders approve reverse stock split authorization

TENAX THERAPEUTICS, INC.

Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.
For: 6,198,812; Against: 5,364,151; Abstain: 23,186; no broker non-votes.
Adjournment proposal also approved (6,308,531 for, 5,052,193 against) but not used.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TENAX THERAPEUTICS, INC. shareholders approved Approve amendment to certificate of incorporation to authorize a reverse stock split at the 2023-11-30 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-11-30

Exact text from the filing

The vote for this proposal was 6,198,812 shares for, 5,364,151 shares against, 23,186 shares abstaining, and no broker non-votes.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TENAX THERAPEUTICS, INC. shareholders approved Adjournment of Special Meeting to permit further solicitation and vote of proxies at the 2023-11-30 meeting.

Outcome: passed
Meeting: 2023-11-30

Exact text from the filing

The Adjournment Proposal was approved at the Special Meeting, with a vote of 6,308,531 shares for, 5,052,193 shares against, 225,425 shares abstaining, and no broker non-votes.

View on SEC.gov

289 shareholder votes filed in the last 30 days. Browse all shareholder votes →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-23-015069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.